StemCell Therapy

Comments(0)

The Ferndown Branch of Arthritis Care is hosting an Arthritis Awareness Day on Wednesday 10th May in support of the National Arthritis Care Week which takes place between 8th and 16th May.

Information talks at set times, demonstrations, discounts, special offers and free samples will be available all day.

The event will take place at St Mary's Church, Ferndown on Wednesday between 10- 4pm.

Professionals will be available to offer free help, medical and non medical advice for people living with or having to manage arthritis.

There will be local support from Lucy Ross-Browne (The Practice Ferndown), Anna Hanson (Bay Tree Health Food Store, Ferndown), Julie de Silver (Ferndown Physiotherapy Clinic), Debbie Haynes, Chiropodist, Ferndown Sports and Leisure Centre, and Arthritis Action.

All are giving their time freely in support of Arthritis Care Week.

Mr Selwyn Richards, consultant rheumatologist, Poole and Bournemouth Hospital, will open the afternoon session with a talk on 'The New and the Old in Arthritis Care Treatment'.

The event is free of charge, and the facilities of the adjoining Beacon Caf will be available throughout the day.

The local Ferndown Branch of Arthritis Care is a social group within Arthritis Care, whose aim is to provide social and friendship events allowing local residents to have at least one to two days out per month.

The meetings are on the first Saturday of the month at the Day Centre, Penny's Walk and members enjoy an hour's entertainment, followed by tea, cake and social interaction. Additionally regular outings in the summer months are provided to ensure no one is house bound and can share in a social event making new friends and acquaintances. At Christmas members enjoy a festive lunch at a hotel in Bournemouth.

The awareness event is for anyone who has arthritis themselves, a family member or friend.

For more information contact Pam Bentley chairman Ferndown Branch Arthritis Care via email asf@arttrailcentre.co.uk or 01202 872074.

Read more:
Arthritis Awareness Day in Ferndown - Blackmore Vale Magazine

Walk to Cure Arthritis Welcomes Ridgefields Dr. Sanjay Gupta of

Orthopaedic Specialists of Connecticut as Event Chair

Chuckie Namiot Of Ridgefield, diagnosed with Juvenille Arthritis in 2011, will show his Zest for Life at the Event

The Arthritis Foundation announced that Ridgefield-resident Sanjay Gupta, M.D. of Orthopaedic Specialists of Connecticut has been named the corporate chair of the 2017 Danbury Walk to Cure Arthritis, which will take place on Sunday April 30, 2107. As chair, Dr. Gupta will provide leadership in helping the event reach its fundraising goal of $75,000.

Dr. Gupta is a long-time Arthritis Foundation advocate and volunteer, and was chosen as the 2017 Walk to Cure Arthritis chair because of his strong leadership skills, passion for helping others and dedication to removing the burden of arthritis from local communities.

The majority of my day-to-day professional life is dedicated to helping people and their families deal with arthritic pain, said Dr. Gupta. The pain of arthritis may not be visible but it is incredibly real and the # 1 cause of disability in America. More must be done to help.

Chuckie Namiot, a 13 year old from Ridgefield deals with that pain on a daily basis. He was first diagnosed with Juvenile Arthritis in 2011 and will participate in the Walk to Cure Arthritis with his team named Chuckie is Awesome. Despite the daily challenges that he faces from his illness, he continues to show a zest for life that has always been his signature trait. Even with the pain Chuckie endures, he is a driven competitor in sports. Cycling has become his passion. In 2014 he received a silver medal in the Connecticut State Time Trial. In the past, he has been involved in youth wrestling and football. Chuckie is known for his empathetic nature. Regardless of how his body feels, he would rather make others feel better than worry about himself. There is no doubt that trait will serve him well in the future when he plans to become a Pediatric Rheumatologist to help others like him.

The Arthritis Foundations Walk to Cure Arthritis is an annual, nationwide fundraising event focused on accelerating the search for a cure and building a better life for the 50 million Americans, including 300,000 children, living with this painful and debilitating disease. In Connecticut more than 663,000 adults and an estimated 3,400 children have arthritis the nations leading cause of disability.

Dr. Gupta is an orthopedic surgeon with Orthopaedic Specialists of Connecticut and widely recognized as one of the top joint replacement surgeons in the state. He is currently the chief of orthopedics at Danbury Hospital. He completed a two-year fellowship at the Hospital for Special Surgery in New York and specializes in hip and knee disorders and joint replacement. The physicians at Orthopaedic Specialists of Connecticut trained at the top hospitals and universities in the country. Recent data shows that they have the best surgical outcomes in the area. Dr. Gupta and his family reside in Ridgefield.

The Walk to Cure Arthritis is nationally sponsored by Amgen.

About the Arthritis Foundation

The Arthritis Foundation (Arthritis.org) is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundations goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride towards a cure. The Foundation also publishes Arthritis Today, the award-winning magazine that reaches 4 million readers per issue.

Photo: Dr. Sanjay Gupta

Follow this link:
Walk to Cure Arthritis is Sunday, April 30 - HamletHub

GETTY

Its often associated with the elderly, but both men and women can start to develop arthritis symptoms from their 40s, and thousands of even younger people are diagnosed each year too.

There are around 200 types of the disease, which causes agonising inflammation and stiffness in the joints, but osteoarthritis and rheumatoid arthritis are the two most common forms.

Osteoarthritis also known as wear and tear arthritis - is caused when the cartilage lining of the joint fails to repair, pushing tendons and ligaments to work harder and triggering swelling and rubbing on the bone.

Rheumatoid arthritis, which occurs when the bodys immune system inflames particular joints, affects three times as many women as men and there are 20,000 new cases every year.

But any type of arthritis can have a devastating impact on peoples lives - 68% of sufferers have reported depression when the discomfort is at its worst, and a survey released last month by Arthritis Research UK found that 600,000 sufferers miss out on work.

The Arthritis Foundation stresses that its not a disease of old age, and that spotting it early is key to effective treatment.

GETTY

While its more likely in those who are overweight, smoke, eat a poor diet, have injured a joint or have a family history of the disease, arthritis can affect anyone.

While its more likely in those who are overweight, smoke, eat a poor diet, have injured a joint or have a family history of the disease, arthritis can affect anyone.

Keep an eye out for these seven main symptoms:

Painful joints

This is the most common indicator that you could have arthritis, however the level of discomfort varies from one person to the next.

Soreness can be felt in any joint in the body, but according to the NHS rheumatoid arthritis normally begins in the hands and feet, and osteoarthritis in the knees, hips and hands.

Restricted movement

You may start to notice that you cant move particular joints as well for instance, if arthritis is in your hands you may struggle to bend them to form a fist.

The NHS explains that this stiffness can be particularly apparent when you wake up in the morning, or after other periods of inactivity, and will disappear within 30 minutes with osteoarthritis, but may take longer to wear off if rheumatoid arthritis.

Getty

1 of 12

GETTY

Swollen joints

Swelling around joints can mean one of two things according to the NHS: an injury or arthritis. So if no injury has occurred, it may be the latter.

The Arthritis Foundation adds that if swelling lasts for more than three days, or happens more than three times a month, you should see a doctor.

Warm and red joints

Inflamed joints can not only indicate arthritis, but also point to which type you may have.

The Arthritis Foundation explains that in rheumatoid arthritis there is often warmth and redness because your immune system attacks the lining of the joint, causing it to become inflamed.

In osteoarthritis, theres usually only minimal redness and warmth, while if its psoriatic arthritis another common type - redness usually hits knees, ankles, fingers and toes.

Noisy joints

Popping and snapping caused by air bubbles in the liquid around your joints - can be common in perfectly healthy individuals, but the Arthritis Foundation warns that when this is accompanied by pain, it may be a sign you have arthritis.

GETTY

Muscle loss

A feeling of weakness and weight loss due to diminishing muscle, and consequently struggling to lift items that you could weeks previously, may also be an indicator say the NHS.

Feeling tired

The bouts of pain that come with arthritis can mean many sufferers fail to get a good nights sleep.

The Arthritis Foundation also says that the disease interferes with the bodys production of red blood cells, responsible for carrying oxygen around the body, which in turn can trigger fatigue-inducing anaemia.

Therefore, if you go from having lots of energy to always feeling lethargic, arthritis could be responsible.

While there is no known cure to arthritis, there are treatments to minimise its impact on sufferers.

For osteoarthritis, anti-inflammatory and pain relief medication is usually prescribed, with surgery also an option in very severe cases.

To slow down the progress of rheumatoid arthritis and damage to joints, doctors will suggest painkillers, anti-rheumatic drugs, physiotherapy and regular exercise.

If youre unsure, visit your GP.

Visit link:
Arthritis symptoms: Seven signs YOU could be suffering | Health ... - Express.co.uk

PINAR DEL RIO, CUBA At age 71, Cuban peasant Pepe Casaas fends off the typical aches and pains of his age in a unique, and effective, way. His secret: letting himself be stung every now and then by a scorpion, the venom of which has analgesic and anti-inflammatory properties.

Although anyone who has been stung by a scorpion says that it hurts a good deal, for Pepe it's "just a minor sting," which he endures at least once a month using one of the three or four scorpions that he keeps close at hand in his house.

"The sting doesn't hurt me a bit. And if they're using it as a treatment for cancer in Cuba, it has to be good," said Pepe, who sometimes keeps a scorpion in his hat in case he starts to feel a pain he needs to treat.

CUBA STARTS OFFERING HOME INTERNET SERVICE, BUT FEW ARE BUYING

"About eight years ago, I started with this scorpion stuff. My bones were beginning to hurt me, arthritis, and it helped me to feel comfortable," Pepe told EFE at his home in the town of Los Palacios in Cuba's far western province of Pinar del Rio.

"I couldn't brush my teeth, or comb my hair. I got a scorpion, squeezed it, and it stung me twice, and look: My arm's doing fine."

Pepe, who comes from a family of beekeepers, began using insect bites starting with bee stings as a remedy against pain. He even says his brother cured himself of a disability thanks to bee stings.

FROM MILK TO LIGHTBULBS, FIDEL CASTRO RESHAPED LIFE IN CUBA

Although Pepe's strategy might seem strange as a way to combat the aches and pains that come along at his age, it is a fact that scorpion venom is used in Cuba as the main ingredient in Vidatox, a homeopathic medication that is prescribed mainly to alleviate pain and other symptoms associated with cancer.

In 2006, Cuba started clinical trials to test the efficacy of scorpion venom in cancer treatment and researchers quickly noted that patients' quality of life was substantially improved.

SCORPION STINGS MAN ABOARD UNITED AIRLINES FLIGHT

In 2011, the Cuban pharmaceutical firm Labiofam began manufacturing Vidatox.

"A very important use of Vidatox, which we want to promote, is that of an analgesic and anti-inflammatory, for use against cancer, given that any osteoarthritic process such as rheumatism can be treated with this medication," Dr. Fabio Linares, who heads the Vidatox project, told EFE.

According to Linares, "it makes sense" that Pepe feels better after a scorpion sting, since in addition to its analgesic effect, the venom stimulates the body's natural curative mechanisms and immune system.

In a laboratory in the city of Cienfuegos, where the Vidatox project is under way, Linares' team is raising some 7,000 "blue scorpions" (Rhopalurus junceus, a species endemic to Cuba) and is taking 10 or 12 venom extractions from each of them every year before releasing them back into the environment.

Some 17,000 bottles of Vidatox are produced and sold over the counter every year in Cuba and in 15 other countries around the world.

In Cuba alone, an estimated 65,000 people have used the remedy to alleviate cancer pain.

More here:
Elderly man in Cuba treats arthritis pain with scorpion venom swears by it - Fox News

By Ruthie Hawkins

Over 54 million people, about 23 percent of all adults in the United States, suffer from arthritis, the Centers for Disease Control and Prevention (CDC) reports.

According to research, the risks for arthritis is not equal among men and women. With the exception of gout, women have a significantly higher risk for nearly all types of arthritis and in particular osteoarthritis of the knees.

Could you have arthritis and not know? To help you return to your regularly scheduled lifestyle, here are seven signs of arthritis every woman needs to know.

1. Catching Also known as grinding, if joints like your knees or wrists feel like their tendons are tangled or catching on another, this is an early symptom of arthritis.

2. Fatigue With rheumatoid arthritis (RA), the immune system attacks the joints, in turn, leaving your body feeling fatigued. A loss of appetite, which can also induce fatigue, can also be an underlying symptom of arthritis.

3. Chronic Inflammation Flare-ups or a periodic increase in inflammation is a common symptom of rheumatoid arthritis, the Arthritis Foundation says.

4. Poor Range of Motion Less mobile than years before? Cant seem to reach for the top shelf without difficulty? These range-of-motion issueswhen accompanied with painoften point to arthritis, experts say.

5. Redness and Rash Though rare, in some cases, redness and rash may present itself, pointing to a condition called psoriatic arthritis. Red, flaky, and scaly in appearance, this inflammatory condition is incurable (but treatable) and may cause flares of joint pain, stiffness, and swelling especially in the morning hours. Even mild skin psoriasis can have a significant degree of arthritis, the National Institutes of Health (NIH) says.

6. Stiffness For many, arthritis begins with the inability to fully extend or bend a joint. Your joints may feel stiff, tight or full due to inflammation. Fortunately, experts suggest starting your day with a simple stretch session will reduce this symptom.

7. Swelling When comparing your joints, if one appears larger or puffier than the other assuming its not due to a previous injury that swelling may be indicating an underlying issue with arthritis.

Follow this link:
Seven Arthritis Signs Every Woman Should Know - Tri County Sentry (blog)

Editors note: Have you seen the Dogster print magazine in stores? Or in the waiting room of your vets office? This article appeared in our April-Mayissue. Subscribe to Dogster and get the bimonthly magazine delivered to your home.

It seems like yesterday I was trying to tone down Chippers leaping, sprinting and quick-turn maneuvering especially inside my home. I envied her nonstop energy. Now nearing her 14th birthday, my slow-moving Husky-Golden Retriever mix needs time to rise up from a nap and to steady her legs.

Chipper has arthritis in the spine and, like many of you with dogs dealing with arthritis, I ache emotionally each time I watch my good old dog walk gingerly, wince or let out a short yip from pain. Its tough to find specific statistics on the percentage of dogs who develop arthritis, but arthritis is more apt to strike large breed dogs like German Shepherds, Golden Retrievers and Labrador Retrievers; dogs with long backs like Dachshunds and Pembroke Welsh Corgis as well as any canine who is overweight or, worse, obese.

So, what do you do to relieve pain and mobility limitations in your arthritic dog and more importantly, what can you do to possibly even prevent this disease from showing up?

Two simple but powerful solutions: exercise and diet. By keeping your dog engaged in some form of daily exercise, you can prevent him from transforming into a canine couch potato. By not dishing up overflowing bowls of kibble and excessively heaping on treats, you can keep him from morphing into a hairy ottoman.

Research conducted in 2015 by the Association for PetObesity Prevention found that more than one half of adult dogs in the United States are overweight. Sporting extra pounds not only spurs arthritis, diabetes and heart disease but reduces the dogs life span by two to five years compared to dogs kept at healthy weights and exercised regularly.

Combining an exercise routine (like taking daily walks on level surfaces, rolling the ball during fetch sessions and swimming in safe bodies of water) with proper diet that keeps your dog at a healthy weight can positively affect the health of your dog, declared Nancy Soares, D.V.M., president of the American Animal Hospital Association and owner of the Macungie Animal Hospital in Macungie, Pennsylvania.

Dog swimming by Shutterstock

Denis Marcellin-Little, DACVS, DECVS, a certified canine rehabilitation veterinarian and associate professor of orthopedics at North Carolina State in Raleigh, added, Being overweight can certainly accelerate the progress of osteoarthritis and make mobility much more limited. Mobility is immensely important in dogs for their longevity, comfort and joy.

And heres a surprising fact: Excessive fat tissue not only packs on the pounds and impairs mobility, but these tissues (known asadipose tissues) actually secrete hormones that promote pain.

Adipose tissue is a major endocrine organ within the body that secretes hormones and other substances, and these substances secreted trigger an inflammation cascade, which brings about pain, Dr. Soares explained.

Even if your dog is diagnosed with arthritis, be it in the form of hip dysplasia, osteoarthritis of the knee or other joint, our experts assessed some tactics to ease the aches and pains:

Consult your veterinarian about the possible benefits of providing supplements like glucosamine, chondroitin and MSM to your adult dog before or at the early signs of arthritis. While most products in this category are not studied and cannot make claims regarding their efficacy, anecdotally, anti-inflammatory benefits can be seen, Dr. Soares said.

Acupuncture, therapeutic massage, hydrotherapy and laser therapy may be beneficial, but make sure theyre administered by certified professionals. Hydrotherapy is a form of exercise, so it is effective, but realistically, it is easier to take your dog on a walk than finding a place that offers an underwater treadmill, Dr. Marcellin-Little said.

Pain management medications prescribed by a veterinarian, such as anti-inflammatories and analgesics, can reduce swelling and pain in the joints, but steer clear of human medications like acetaminophen (Tylenol) or ibuprofen (Advil), as they are both extremely toxic to dogs.

Yes, some dogs do well with joint replacement surgeries, but make sure the operation is performed by a board-certified orthopedic surgeon. Our pets deserve specialty treatment when advanced care is warranted, Dr. Soares said.

There is limited clinical evidence to support the expense and invasiveness of stem cell therapy, Dr. Soares said. Additional research is underway to determine the best treatment and efficacy for the best outcome.

A holistic option being hailed by veterinarians and physicians is turmeric, a powerful spice that new studies show has the ability to help lessen arthritic inflammation. Also consider adding turmeric root to your dogs diet as a preventive aid in the battle against arthritis. A little bit goes a long way (see our suggested recipe that includes turmeric root powder).

The parting message: The big three weapons in combating osteoarthritis in dogs are managing pain with medications, losing excess weight and exercising regularly to help your dog stay strong and have good joint mobility, Dr. Marcellin-Little said. Your dog will feel better and move better and, hopefully, enjoy a long, quality life.

Spices by Gina Cioli/Lumina Media

Check out this recipe for Golden Paste by Australian veterinarian Doug English (BVSc) from his website turmericlife.com.au. As always, consult with your veterinarian for best treatments for your pets specific health issue.

Ingredients:

Directions:

Continued here:
How to Relieve Arthritis Aches in Your Dog - Dogster - Dogster.com

According to recent studies, arthritis affects approximately one-third of all adult farm and ranch operations and is considered one of the leading causes of disability by customers of the U.S. Department of Agricultures AgrAbility Project. It tends to affect most ag industry workers in their hands, knees and hips mainly because these are the joints that take the most pressure.

Trauma to these joints in relation to farming and ranching occurs when jumping off tractors, being kicked by large livestock or constant bending when milking cows. It can also occur from repetitive motions such as gripping tools, walking on cement floors or locking knees when riding in vibrating machinery all day.

There is no known cure for arthritis but it can be managed so that its progress is slowed and its effects minimized. That management should begin with an arthritis team that can involve your family doctor, a rheumatologist, the pharmacist, and in some cases a physical therapist and occupational therapist. There are going to help you with the most important step which is a diagnosis and treatment program.

When it comes to farming and ranching, there are some pain management practices that you can follow to ease the burden. Some of those practices are:

Maintaining a healthy weight and lifestyle;

Quit smoking;

Avoid gripping and grasping for long periods of time;

Organize the day by ranking the days tasks in order of importance;

Use built-up handles on toolsrubber hose or washcloths can help;

Wearing quality, nonslip footwear;

Use the largest joint possible to complete a task; and

Simplify your work with labor saving devices.

These are just a few techniques that you can use to alleviate arthritis pain encountered during you daily work. For more information concerning arthritis and agriculture, research the following resources: http://www.arthritis-ag.org, http://www.agrability.org/resources/arthritis, and

http://www.arthritis.com.

Farmers and ranchers may extend productive life in agriculture if they are willing to commit to controlling their arthritis by diet, exercise, modifying their work, and respecting their limitations.

Go here to read the rest:
Arthritis affects agriculture - High Plains Journal

My aching joints make it hard to walk. If you have heard yourself, or a loved one, say these words then continue reading.

Many people accept chronic joint pain as a normal part of life, often assuming nothing can be done. But, there is good newsboth non-surgical and surgical treatment options are available that can help relieve, if not eliminate, chronic arthritis pain.

Arthritis is quite commonabout one in every five adults in the U.S. is affected by it. Arthritis is a general term referring to the inflammation and pain caused by more than 100 different types of joint conditions and diseases. The most common type is osteoarthritis, a degenerative disease that causes the cartilage between the joints to wear away. Because arthritis is complex, it should be diagnosed by a doctor, who can recommend treatment options.

Arthritis can affect anyone, regardless of age or gender. The Centers for Disease Control and Prevention estimates that more than 50 million adults and 300,000 children in the country have some type of doctor-diagnosed arthritis. More common in women than men, the pain usually worsens with age for both as joints further wear down. Carrying excess body weight can also cause issues with joints and worsen arthritis pain.

Living with arthritis and chronic joint pain can be overwhelming. Many people seek relief from over-the-counter anti-inflammatories like ibuprofen. Hot and cold compress therapy can also be used help reduce inflammation. Additionally, low-impact exercises like walking, cycling or water aerobics can help to ease arthritis pain by keeping joints moving and strengthening surrounding muscles.

Weight plays a significant role in joint stress so when people are overweight it puts stress on their joints, especially their weight-bearing joints like knees and hips. Every pound of excess weight exerts about 4 pounds of extra pressure on the knees. That is part of the stress on the body of people who are overweight, causing them to be at greater risk of developing arthritis. Losing even 10 percent of extra weight can have an impact on reducing pain and restoring joint function.

Other options to compliment or reduce the use of over-the-counter treatments are injections. The most common injections are corticosteroids and hyaluronic acid, to provide arthritis pain relief. These are inserted directly into the hip or knee joint by an orthopedic surgeon and can provide continuous relief that can last for several months.

If managing the pain is no longer effective, then surgical options like total joint replacement can provide a life-changing option to help restore mobility. The good news is that community members do not have to leave town to receive joint replacement surgery.

Centennial Orthopedics and Podiatry, located in Roseburg, offers a full range of diagnostic procedures, and surgical services, including total hip, knee and ankle joint replacements. A minimally invasive surgical procedure, anterior hip replacement, is also available locally and has shown to reduce recovery time significantly so patients can get back to enjoying life and the activities that may have been difficult in the past like traveling, gardening, climbing stairs and exercising. The majority of patients who have joint replacement procedures and prepare for their surgery by exercising and building strength are generally able to walk immediately after surgery with reduced pain.

CHI Mercy Healths New Strides Joint Center is designed to help patients both before and after surgery. New Strides nursing and physical therapy teams work closely with community surgeons to help ensure the best outcomes. They educate patients through every step of the procedure so they know what to expect to help reduce anxiety and prepare for their surgery and recovery. New Strides staff uses a unique group approach to physical therapy classes immediately after surgery to aid and track recovery. Mercys New Strides staff also works with patients to ensure their home environments are well-suited for their return, within a day or two, after surgery.

Everyones experience with arthritis is different. But, there may be options available for relief so you dont have to live with chronic pain. My advice to anyone suffering from hip or knee joint painreach out to your physician or call our office at 541-229-2663 to explore your treatment options. Its time to get your life back, and we can help.

Dr. Cary Sanders is an orthopedic surgeon at Centennial Orthopedics and Podiatry, a division of Centennial Medical Group in Roseburg.

Reporter Dan Bain can be reached at 541-957-4221 or e-mail at dbain@nrtoday.com.

Read more:
Finding long-term arthritis pain relief - NRToday.com

WATCH THE LATEST DELAWARE, NATIONAL NEWSKJWP NewsBreak | 0:58

President Trump's "America First" tour; One hurt in Elsmere fire; Aaron Hernandez found dead

1 of 3

Facebook Killer found dead in PA; Suspect arrested in harassment of UD students; Atlas Cargo launch to the ISS

2 of 3

MANHUNT OVER: Facebook killer found dead; 3 shot in Dover; Theresa May calls for Early General Election

3 of 3

KJWP NewsBreak

KJWP NewsBreak

KJWP NewsBreak

The U.S. Food and Drug Administration rejects the approval of baricitinib, an arthritis medicine submitted by Alapocas-based Incyte and Indianapolis-based Eli Lilly.(Photo: SUCHAT PEDERSON/THE NEWS JOURNAL)Buy Photo

The U.S. Food and Drug Administration declined to approve baricitinib, a potential rheumatoid arthritis medicine developed byIncyte and Eli Lilly & Co.

Baricitinib was expected to win approval in the United States and generate more than $2 billion in peak sales for the companies, according to Incyte's regulatory filings. In fact, executives at both Indianapolis-based Eli Lilly and Alapocas-based Incytepredicted the medicine would challenge market leader Pfizer's Xeljanz.Worldwide, Xeljanz generated more than $927 million in sales in 2016, up 77 percent over 2015 numbers.

"This is certainly a blow," said Jim Butkiewicz, chair of the University of Delaware's economics department. "They are going to have to pay a team to work on this getting approved, and the drug's potential revenue will be delayed for at least another year. This is a setback, no question about it."

European regulatory authorities approved baricitinib last month.

In a letter to the companies, the FDA said it needed more clinical data to determine the most appropriate doses. The agency also requested additional information about risks mixing the drug with other treatments.

"The companies disagree with the agency's conclusions," both Lilly and Incyte said in a statement. "The timing of a resubmission will be based on further discussions with the FDA."

Catalina Loveman, a spokeswoman for Incyte, did not respond to requests for additional comments.

"We are disappointed with this action," said Christi Shaw, president of Lilly Bio-Medicines, in a statement. "We remain confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate-to-severe rheumatoid arthritis."

The rejection will sting both companies. Incyte and Lilly had been working on the drug since December 2009. Under the partnership agreement, Incyte agreed to cover 30 percent of baricitinib'sPhase III trials, estimated to cost over $500 million, in exchange for as much as 29 percent of the drug's sales.

"Pharmaceutical companies invest so much in research and development, and if the drug doesn't succeed, those costs need to passed on elsewhere," Butkiewicz said. "That's always the justification given for why pharmaceutical prices are so high because they have to cover the cost of research."

Wall Street analysts said they expect the FDA's denial will impact Incyte's earnings. Piper Jaffray analyst Josh Schimmer downgraded Incyte in a note issued to investors, calling baricitinib "an important part of the valuation and outlook for us." Michael Schmidt, analyst with Leerink, said that baricitinib contributed $25 to estimated Incyte stock price of $141 per share. Schmidt estimated in a research note that a one-year approval delay would be "a best case scenario."

Incyte's stock was battered by the rejection. After hitting a high of $141.23 per share last week, the stock closed Tuesday at $125.90. Eli Lilly shares also reflected the bad news dropping from $86.15 per share on Thursday to $81.20 at Tuesday's closing.

Separately, Incyte increased the executive compensation for its chief executive officer, HerveHoppenot, that it announced in a Monday regulatory filing with the Securities and Exchange Commission. Hoppenot's base salary jumped to $937,738 last year from $898,800 in 2015. Incyte also increased its stock and option awards to $9.5 million in 2016 from $3.7 million in 2015. That brings his total compensation package to $11.8 million last year from $6 million.

Since leaving Novartis for Incyte in 2014, Hoppenot has guided the company into the prestigious Standard & Poor's 500, an index of the most widely held stocks on the New York Stock Exchange and Nasdaq.

Incyte joined the list nearly one week after it reported its 2016 revenue surpassed $1 billion for the first time in the company's 26-year history. The $1.1 billion revenue represented a 47 percent increase from the $753 million it generated in 2015.

The company's growth was largely fueled by the success of Jakafi, a medicine approved in the United States and Europe to treat two rare blood cancer. Jakafi sales hit nearly $853 million last year, and Incyte expects the drug to generate $1 billion in sales this year.

Contact Jeff Mordock at (302) 324-2786, on Twitter @JeffMordockTNJ orjmordock@delawareonline.com.

Read or Share this story: http://delonline.us/2pyo9Qp

Continue reading here:
FDA rejects Incyte arthritis drug baricitinib - The News Journal

GETTY

The autoimmune condition causes pain, stiffness and swelling in the joints, usually in the hands, feet and wrists.

Its the second-most common form of arthritis, affecting one per cent of the UK population - approximately 690,000 people - and there are 20,000 new cases per year, according to The British Society for Rheumatology.

However, ground-breaking new research may have discovered a way to stop or reduce impact, and control its severity, by spotting and treating symptoms in the early stages.

The joint study by the University of Manchester and University of East Anglia found that patients who were prescribed drugs within the first six months of symptoms appearing had a significantly improved ability to walk, grip and dress themselves over the next 20 years, than others who were treated later.

GETTY

The study is one of a number of significant advances in knowledge about rheumatoid arthritis over the past 20 years.

Whats more, the researchers also found treating patients with the disease-modifying drugs - including sulfasalazine, methotrexate and steroids - also gave them a lower risk of dying once the disease was brought under control.

In their research, the study authors examined the cases of 602 patients with rheumatoid arthritis across two decades between 1990 to 2010.

Though there is a broad range in terms of how people are affected by the disease, the number of patients whose lives have improved has increased thanks in part to early treatment, says James Gwinnutt, first study author from The University of Manchester.

Early intervention has become more and more common in the NHS over these past 20 years. In the early 1990s early intervention would happen in about 30 per cent of cases. Nowadays, that figure is probably more like 60 to 70 per cent.

The study is one of a number of significant advances in knowledge about rheumatoid arthritis over the past 20 years.

GETTY

Getty

1 of 12

It is also encouraging to hear about the progress that has been made. This study confirms how important early diagnosis and the commencement of treatment is, says Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK.

Its an incredibly painful condition that can be diagnosed at any age and have an impact on a persons everyday life.

The British Society for Rheumatology describes the first weeks and months following the onset of the disease as the window of opportunity, explaining treatment early in the disease - even within the first 12 weeks - can prevent damage to joints and other organs, improve long-term function, and increase the likelihood of achieving disease remission.

As well as making everyday tasks increasingly difficult, without adequate treatment the life expectancy for a suffer can be shortened by three to seven years and 10 to 15 years in severe cases.

Other research has highlighted a number of lifestyle factors that can reduce risk and severity of rheumatoid arthritis.

GETTY

A study published this month in the Annals of Rheumatic Disease found a healthier diet when youre younger can reduce risk, particularly in women who experience an onset of the condition before the age of 55.

The researchers also found lowering BMI, increasing fatty acid intake and having a modest alcohol consumption has a positive effect.

Furthermore, getting enough vitamin D also helps by reduce inflammation, strengthen bone cartilage, and minimise pain and risk for disability in sufferers, according to another 2004 study published in Arthritis & Rheumatism.

According to the NHS, its not known why the immune system attacks the cells that line your joints by mistake, triggering rheumatoid arthritis, but those at increased risk are women, smokers and those with a family history of the condition.

While theres no cure for rheumatoid arthritis, treatments include long-term medication that can relieve symptoms, physiotherapy or occupational therapy to keep you mobile and surgery to correct joint problems that may develop.

Read more:
Rheumatoid arthritis cure: Symptoms halted by doing THIS (it could prevent joint damage) - Express.co.uk

BALTIMORE Vizuri Consumer Healthcare on Tuesday launched PainBloc24, a 24-hour over-the-counter topical pain reliever for arthritis joint pain. PainBloc24 has been clinically shown to help relieve pain with as little as one application per day, the company stated.

This is a great milestone for our company, and we know the 53 million people who suffer from chronic arthritis pain need a longer-lasting pain reliever," stated Jeremy Puttock, VP Vizuri Consumer Healthcare. "Were proud to bring a true breakthrough to the market and look forward to expanding distribution in the coming months.

The patent-pending NeuroMax technology in PainBloc24 delivers the maximum allowable OTC dose of its pain-blocking medicine, capsaicin, to turn off certain nerve fibers that send pain signals to the brain. In a clinical study, 60% of patients reported a reduction in arthritic knee pain for 24 hours following one-to-two daily applications of PainBloc24. In addition, patients who used the product for just seven days continued to experience relief from their arthritis pain for an additional three weeks after the last application.

PainBloc24 is available exclusively online and will be rolled out to food, drug and mass retailers this summer.

The rest is here:
Vizuri Consumer launches topical analgesic for 24-hour arthritis relief - Drug Store News

GETTY

Saturated fat has long been a prime suspect in the onset of osteoarthritis, after researchers found it changes the composition of cartilage, but scientists now believe carbs may also wreck joints.

The research, published today in Scientific Reports, was conducted by Professor Yin Xiao, from Queensland University of Technology's Institute of Health and Biomedical Innovation.

They studied the effects on joints of diets rich in a variety of saturated fatty acids found in such foods as butter, coconut oil, palm oil and animal fat, and simple carbohydrates - a high-fat, high carbohydrate diet common to "junk food".

They reckon junk food changes the chemical composition of load-bearing joints that makes them weaker, eventually leading to painful osteoarthritis.

Professor Xiao said: "Our findings suggest that it's not wear and tear but diet that has a lot to do with the onset of osteoarthritis.

GETTY

"The main function of cartilage is to seal the bone ends in a joint and absorb pressure on the bones during weight-bearing movement such as walking.

"We found that a diet containing simple carbohydrates together with 20 per cent saturated fats produced osteoarthritic-like changes in the knee.

"Saturated fatty acid deposits in the cartilage change its metabolism and weaken the cartilage, making it more prone to damage.

Getty

1 of 12

"This would, in turn, lead to osteoarthritic pain from the loss of the cushioning effect of cartilage.

"We also found changes in the bone under the cartilage on a diet rich in saturated fat."

PhD student Sunder Sekar said the team tested lauric acid, a saturated fatty acid found in coconut oil.

GETTY

He said fatty acids could cause tissue inflammation in the entire "joint environment".

He said: "Interestingly, when we replaced the meat fat in the diet with lauric acid we found decreased signs of cartilage deterioration and metabolic syndrome so it seems to have a protective effect.

"We tested a variety of saturated fats and found that long term use of animal fat, butter, and palm oil could weaken the cartilage.

"Replacement of traditional diets containing coconut-derived lauric acid with palm oil-derived palmitic acid or animal fat-derived stearic acid has the potential to worsen the development of both metabolic syndrome and osteoarthritis."

The study is supported by the Prince Charles Hospital Research Foundation.

Read the rest here:
Arthritis warning: Eating THESE types of food can 'lead to joint ... - Express.co.uk

Stock images, St. George News

ST. GEORGE Rheumatoid arthritis is a disease condition that seems to be on the rise and it can affectanyoneregardless of gender, race or age; there areimperative facts you need to know about thiscondition that is becoming more serious every day.

Rheumatoid arthritis is a health condition that causes repeated swelling of synovial tissues around the joints. According to William Shiel, author and editor of Medicine.Net, RA is an autoimmune illness that can also result when body muscles are wrongly attacked by yourown immune system.

The effects of rheumatoid arthritis health condition have greatly impacted many people both socially and economically. This disease has caused suffering and huge economic losses to its victims and their relatives in treatment and management of the condition.

RA is increasingly becoming a common disease that is affecting almost 1 percent of the global population. In the United States, the disease has affected close to 1.3 million people, as revealed by most recent census findings reported by the Arthritis Foundation on arthritis.org.Although the disease can affect anyone regardless of gender, race or age, the statistics reveal itis more common inwomen than men, with 2 out of 3 victims of the condition likely to be women.However, it has been manifested mostly in people between the ages of 30 and 60 years old.

Because RAis acontinuing illness that advances with time, it is necessary to create maximum cognizance so that the health risk can be handled in the best way possible.

Causes

Although it is not clearly established what initiates RA onset, there are a number of most probable causes of this health condition. The major contributing factor of RA illness is anomalous reaction of the immune system against its own body; that is, abnormal or other than as expected.

Genetic composition is yet another probable cause of Rheumatoid Arthritis. Cases of the same family members suffering from RA have provided critical leads to researchers in establishing genetic factor as a potential cause of RA. Consequently, the prevalence of the condition in women more than in men points out that body hormonal composition also determines the probability of suffering from RA condition.

Environmental factors such as pollution and chemicals contamination have also been suspected of causing this joint disease. Exposure to certain bacteria and virus can also initiate RA.

Symptoms

RA symptoms may remain undetected until late stages of the illness. When the condition has advanced, victims may experience painful, soft and swollen joints. This joint problem is commonly replicated in more than one part of the body with the matching joints in both left and right sides of the body being affected.

Apart from joint complications, many RA victims can experience mild fatigue and fever. The symptoms of RA may be occurring with an on-and-off pattern. When the inflammation and pain become intense, they cause a flare situation that may require quick medical attention.

Other symptoms of RA include red eyes, dry mouth, red skin around the joints, limping and inflamed lungs leading to shortness of breath.

Diagnosis

The best specialist to diagnose RA is a rheumatologist. This is a trained medical personwho has adequate knowledge and skills in dealing with Rheumatoid Arthritis.

A rheumatologist may follow one or more procedures in making adiagnosis: He may give a set of questions to the victimthat can be vital in determiningindications of RA. He may inquire about the victims medical past that touches on boththe patient and their relatives. The rheumatologist can also conductother tests such as physical examination, blood analysis, imaging scans and antibodies assessment. It is essential to note that one test may not be adequate to diagnose rheumatoid arthritis and therefore specialists should combine a number of tests to arrive at a conclusive diagnosis.

Treatment

If you or someone you know is a victim of rheumatoid arthritis, itis very important to deliberate on various ways of treating this increasing and distressing health condition. Treatment of RA is aimed at achieving various objectives such as stopping inflammation, preventing tissue damage, improving physical performance of the patient and relieving pain.

Doctors should conduct aggressive treatment procedures initially aimed at stopping or minimizing inflammation. Treatment can completely minimize the conditions activity thus causing tight control of RA.

Different drugs are used in management and treatment of RA. Anti-inflammatory medications such as nonsteroids can be bought from chemists with a specialists instruction. Such drugs include ibuprofen and ketoprofen. Corticosteroids can also be used to quickly manage inflammations. Lastly, illness altering anti-rheumatic medicines such as sulfasalazine can be administered in treatment of rheumatoid arthritis.

Written by JUDD LaROWE, M.D.

Dr. Judd LaRowes private practice is River View Medical Walk-In Clinic, 1664 S Dixie Drive.in St. George, telephone 435-656-2995 He is also an Intermountain Healthcare provider of internal medicine affiliatedwith Dixie Regional Medical Center.

Email: news@stgnews.com

Twitter: @STGnews

The rest is here:
What you need to know about rheumatoid arthritis - St George News

AbbVie (ABBV) will get some breathing room in rheumatoid arthritis after Eli Lilly (LLY) and Incyte's (INCY) drug was hit with delays by the Food and Drug Administration over the weekend, leaving Lilly to instead focus on a Pfizer (PFE)-rivaling breast cancer med.

On Friday, theFDA asked for more dosing information for Lilly and Incyte's rheumatoid arthritis drug, baricitinib, causing what could be a lengthy delay in its release. So Lilly'sbreast cancer drug known as abemaciclib is now especially important for Lilly, Leerink analyst Seamus Fernandez said.

Abemaciclib could compete against Pfizer's Ibrance and Novartis' (NVS) Kisqali in the CDK4/6 inhibitor market. These drugs aim to inhibit a specific set of enzymes thought to be tied to breast cancer.

"In our Lilly model, we are currently forecasting $1.5 billion global sales of abemaciclib by 2026 with the overall CDK4/6 market reaching more than $10 billion," Fernandezwrote in a note to clients.

Fernandez said abemaciclib could be the next major catalyst for Lilly's stock. Phase 3 data on abemaciclib is expected in June.

"We believe abemaciclib's ability to dose continuously together with a safe and manageable tolerability profile likely will make abemaciclib highly competitive with Novartis' Kisqali and provide opportunities to differentiate from Pfizer's Ibrance on secondary efficacy measures like response rate," Fernandez said.

The analyst kept his outperform rating and 91 price target on Lilly stock.

Lilly shares toppled as much as 5.6% on the stock market today, closing down 4.1% to 82.38, below its 50-day ling and a 83.34 buy point. Incyte stock tumbled 10.5% to 126.07.The delay on baricitinib means it likely won't get FDA approval until 2018 and launch until 2019. That removes a near-term rival for AbbVie's Humira. It also puts Lilly/Incyte seven to eight years behind Pfizer's Xeljanz, and more in line with generic-like competition.

Analysts expect the drug to be delayed at least a year, and shares of Lilly and Incyte toppled early Monday. Baricitinib already has been approved for use in Europe.

While baricitinib is likely delayed, Fernandez expects $1.7 billion in peak U.S. sales when it is approved. And Lilly still benefits from sales in Europe where the drug has attained approval.

IBD'S TAKE:IBD's 43-company Ethical-Drugmakers industry group has risento No. 150 out of 197 groups tracked from No. 184 just four weeks ago. Head to IBD Stock Checkup for a list of the top-rated drugmakers.

Other analysts agreed on the one-year delay for baricitinib, but were more cautious on Lilly's breast cancer drug. BMO analyst Alex Arfaei called abemaciclib "the biggest remaining uncertainty for Lilly in 2017."He sees the data as likely to disappoint.

"We still have not seen much data that would indicate CDK4/6 inhibitors are meaningfully differentiated," he wrote in a report. "Data from (the American Association for Cancer Research) 2017 suggests abemaciclib is not as selective as ribociclib (Kisqali) and Ibrance."

Arfaei cut his price target on Lilly stock to 71 from 73, though he maintained his forecast for 5% sales growth for Lilly in 2017 on its diabetesdrugs Trulicity, Jardiance and Basaglar, and psoriasis drug Talz.

These drugs "should offset the decline of mature franchises," he wrote. "However, from 2015-20, we forecast revenue compound annual growth rate of 4%, below Lilly's guidance of 5% partly because more conservative assumptions for the mature franchises."

RELATED:

Eli Lilly, Incyte Stocks Break Key Levels After FDA Drug Setback

How Biogen's Takeover Prospects Soured In Mere Months

Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives

Eli Lilly could do better than its rivals in diabetes drug sales. (Jonathan Weiss/Shutterstock.com)

4:36 PM ET Eli Lilly is set to outperform bigger drugmakers Novartis and Sanofi in terms of first-quarter diabetes sales.

4:36 PM ET Eli Lilly is set to outperform bigger drugmakers Novartis and...

Read the original:
Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug? - Investor's Business Daily

Each Tuesday, Doctor Rob Riley joins us to answer viewers' medical questions. Here are the questions he addressed on April 18.

"I had a total thyroidectomy back in August. My scar turned into a keloid. What can I do to make the keloid go away?"

Dr. Riley: Keloids are thickened scars. When most people have surgery, the scar that forms can be pretty thin and flat and tends to fade over time. But some of us, due to our genetics, form big, thick keloids instead. They don't generally do harm, but understandably, people don't like the way they look. Silicone sheets can be obtained at the drug store without a prescription and may help keloids to flatten over time. In the office, we can inject these keloids with a cortisone-like preparation which is often effective. There's some evidence to suggest that freezing keloids in the office may be helpful, too. Unfortunately, surgically cutting the keloid out usually results in a new keloid forming, so that's usually tried as a last resort.

"I just found out I have arthritis so bad in my one knee it's bone on bone. I am taking meloxicam and starting therapy soon. Any other over-the-counter meds that will help this?"

Dr. Riley: Meloxicam is an anti-inflammatory medicationlike ibuprofen or naproxen. Some people find they do just as well or better with these over-the-counter meds as they do with the prescription versions. There's also something called capsaicin, which comes as a cream or gel, which can be applied directly over the painful joint several times daily, and some people get some relief from that. When things get to the bone on bone point, we certainly try all the medications possible plus physical therapy, but often times that's when we start to have the conversation about considering knee replacement surgery.

"I have a tender spot on the back of my right ankle that only hurts when I wear tennis shoes. What could that be?"

Dr. Riley: The most common causes of pain in that location are irritation of the Achilles tendon and bursitis from pressure on the little sac that sits just beneath the Achilles tendon. The tendon tends to hurt when the person is using that big calf muscle on the back of their leg, while the bursa is often tender to direct pressure in the area. Both of these are overuse issues, though, so the best initial approach is to back off on painful activity somewhat and give things a chance to heal. If a certain pair of shoes seems to make things worse, then probably the shoes are applying too much pressure in that area and should be avoided. If the simple things aren't taking care of things, a visit to the doctor may be in order. Some medications, some home exercises, and working with a physical therapist may all be effective for this problem.

Dr. Riley joins us from Memorial Family Medicine.

Continue reading here:
Ask the Doctor: Keloids, arthritis, ankle tenderness - WNDU-TV

UA softball Coach Mike Candrea hopes to hit a home run in support of the University of Arizona Arthritis Center and its research efforts at the 2017 Bear Down Luncheon on April 26.

The affiliation between Wildcat athletics and the UAAC is a long-standing tradition that goes back to the early days of Lute Olson. Supporting the UAACs mission and efforts to defeat arthritis as a debilitating disease is a privilege for me, said Candrea, featured speaker at the event.

An eight-time NCAA champion who will be inducted into the coaching Hall of Fame this October, Candrea will share anecdotes and insights gleaned during 32 seasons. Candreas talk is sure to be unforgettable, said Paul Cicala, sports director at KVOA, who will serve as master of ceremonies.

I feel honored to be able to introduce Mike Candrea, who has had an amazing coaching career: He is a UA standout and he is going out of his way, along with doctors at the UAAC, to help others, said Cicala, one of the more than one million Arizonans battling arthritis.

Cicala, who has psoriatic arthritis, said he is proof arthritis impacts those of every age, including children and young adults. Psoriatic arthritis is a chronic inflammatory disease that occurs when the immune system mistakenly begins attacking healthy joints and skin.

I was in my mid-20s and in the best shape of my life. I could still dunk a basketball and I was lifting weights every day when I started having sharp pains in my legs that spread to the rest of my body. My digits on my hands and feet started swelling and they tested me for multiple sclerosis and many other ailments, but they never considered psoriatic arthritis, said Cicala.

Cicalas condition deteriorated rapidly. Walking caused extreme pain, he was unable to open jars or complete simple household tasks and it became increasingly difficult to work. When he was finally diagnosed with psoriatic arthritis, Cicala said the medications Enbrel and Methotrexate saved his life.

I am almost back to being the person I used to be and I am so thankful to the UAAC and all of the fine doctors who continue to do research to find treatments for arthritis. To this day I dont take walking for granted; I take pride in walking when I run errands, walking up A Mountain or Tumacoc Hill and doing other things I thought were taken away forever, he said.

Dr. C. Kent Kwoh, arthritis center director, said the center offers specialized care for patients who are living with cutaneous autoimmune diseases such as psoriatic arthritis, lupus, and scleroderma.

Kwoh said the centers multi-disciplinary approach, which includes bench-to bedside research, also utilizes specialists in orthopedic surgery, geriatrics, immunology, medical imaging, pharmacology, integrative medicine, epidemiology, public health, exercise, nutritional sciences, podiatry and biomechanics.

The list of specialists is expanding with the recruitment of new physicians and the centers ongoing distinction as Arizonas only rheumatology training program for medical students, medical residents and fellows. Kwoh attributes many positive developments to the partnership between Banner and University Medical Center and the continued support of the community and institutions such as the UA Department of Athletics.

There is a shortage of rheumatologists nationwide and here in Tucson. We want to continue to expand our programs to try to meet the need for caring for patients with arthritis in clinics where different specialties can practice together to provide specialized care in an academic medical center. This allows patients to see a number of specialists at the same time or on the same day, which is particularly important for patients with arthritis because these are multi-system diseases, Kwoh said.

Follow this link:
UA softball coach pitches in for arthritis center fundraiser - Arizona Daily Star

By Teresa Rivas

Incyte Corp. (INCY) and Eli Lilly (LLY) are both falling Monday, on news that the FDA issued a complete response letter concerning its rheumatoid arthritis treatment baricitinib, delaying approval.

The FDA didnt kill the drug, but it didnt approve it either, saying that more clinical trials would be needed to determine the correct dosage. Of course, more trials will increase the time and money that the companies will have to spend on baricitinib before its approval. Incyte and Lilly both said they are committed to working with the agency to get approval.

Plenty of analysts are weighing in on the stocks today.BMO Capital Markets M. Ian Somaiya reiterated an Outperform rating but cut his price target on Incyte to $144 from $170:

We are pushing out U.S. launch timelines for baricitinib by three years following CRL where FDA cited need for additional dosing and safety data, implying need for new trials. In our conversation, management suggested that the issue in the CRL was not raised previously by the FDA, nor was it the reason for the recent data submission. Our review of published data suggests that the issue could be related to increase in creatinine phosphokinase (CPK), which can be causing drug-induced myopathy (i.e., alectinib) and addressed via a REMS.

SunTrust Robinson Humphreys Peter Lawson reiterated a Buy rating but cut his price target from $160 to $145:

On Friday the FDA issued a complete response letter (CRL) for the NDA for baricitinib in moderate-to-severe rheumatoid arthritis (RA). This was unexpected considering the strength of the data which was published in highly respected medical journals, and the recent EU approval. The FDA is seeking additional clinical data to determine dose, and to further characterize safety. While still early, we have re-assessed our model, we have assumed a conservative 2 year delay in filing, lowered the probability of success in the U.S, and removed milestone payments.

Raymond Jamess Reni Benjamin reiterated a Market Perform rating on Incyte:

While the timing of the FDAs decision was on the PDUFA date, the CRL certainly came as a surprise to us and, we expect, many other investors given the recent approval of the drug by the European agency as well as the multiple positive phase III results generated during clinical development. Whats more surprising and concerning to us is the agencys request for additional clinical data to determine the appropriate doses and further address the safety concerns associated with the drug, a decision that both companies plan to appeal.

As for Eli Lilly, Credit Suisses Vamil Divan reiterated an Outperform rating but lowered his price target by $1 to $87:

While we like LLY for its diversified new product story, baricitinib is a key component of the story and the press release reads ominously to us. The FDA is requesting additional clinical data to determine the most appropriate doses and also to characterize safety concerns across various treatment arms. The timing of a resubmission is still to be determined but for now we assume it will take at least 12 months, pushing back a US launch to potentially 2019 or later. It will likely also limit the peak potential of the product given the competitive nature of the rheumatoid arthritis market and the fact that we expect PFEs Xeljanz will lose it US patent exclusivity by 2025, opening the door for generic oral JAK inhibitors to enter the US marketOur updated baricitinib estimates, including a 2019 US launch and peak 2025 sales of $1.2Bn in the US and $2.1Bn globally, led to our LLY target price reduction to $87 (from $88).

Incyte is down 11.2% to $125.03 in recent trading, while Eli Lilly is down 3.9% to $82.52.

See the original post:
Incyte, Eli Lilly Tumble As FDA Delays Arthritis Drug Approval - Barron's (blog)

Eli Lilly & Co. (LLY) and Incyte (INCY) chose to disclose the FDA rejection of their rheumatoid arthritis pill baricitinib on Friday, a market holiday, so the repercussions from the regulatory setback are hittingboth stocks Monday.

Lilly shares were down just over 4% to $ 82.33through mid-morningtrading, while Incyte shares were down just over 11% to $125.09

Baricitinib was expected to secure U.S. approval and deliver $2 billion or more in peak sales as the most effective, once-daily oral JAK inhibitor for rheumatoid arthritis, supplanting Pfizer's (PFE) Xeljanz.

Those plans are now on hold indefinitely. In a statement, Lilly said the FDA's complete response letter included a request for additional clinical data to determine appropriate doses of baricitinib. The FDA also asked for more safety data.

Lilly and Incyte said they disagree with the FDA's conclusions and plan to resubmit baricitinib for another shot at approval. A timeline for resubmission was not provided.

The European Medicines Agency approved baricitinib for the treatment of rheumatoid arthritis in February. The drug is marketed there under the brand name Olumiant.

Piper Jaffray analyst Josh Schimmer downgraded Incyte to neutral and cut his price target to $124 from $140. "Incyte has a differentiated flagship product in Jakafi, a leading management team, a strong R&D engine and strategic sense, and still strong growth prospects. But baricitinib in the U.S. was an important part of the valuation and outlook for us," Schimmer wrote, in his downgrade note.

Leerink analyst Michael Schmidt said baricitinib contributes 18%, or $25, to his Incyte $141 price target. "We expect Incyte shares to be weak on Monday given that approximately one-year U.S. approval delay now seems likely in our view, in a best case scenario," Schmidt said in a research note.

Lilly licensed baricitinib from Incyte in 2009. The pharma giant took the lead on the drug's development, conducting all the clinical trials and handling regulatory duties. Lilly retains the bulk of baricitinib's sales under the Incyte licensing deal, so the FDA rejection hits the pharma giant -- desperate for new blockbuster drugs -- particularly hard.

Lilly reiterated 2017 earnings guidance but has not said how the baricitinib setback will impact its 2018 financial outlook.

Why FDA turned away baricitinib is not entirely clear, although analysts speculate regulators picked up a concerning safety signal with the higher 4 mg dose. Pfizer faced the same problem with Xeljanz before FDA ultimately approved a lower dose.

Excerpt from:
Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for ... - TheStreet.com

New Delhi, April 17:

Drug firm Unichem Laboratories today said it has received approval from the US health regulator for Piroxicam capsules, used in the treatment of osteoarthritis and rheumatoid arthritis, in the US market.

In a BSE filing, Unichem Laboratories said it has received ANDA approval from the US Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg and 20mg.

The approved product is therapeutically equivalent to Feldene Capsules 10mg and 20mg of Pfizer Inc.

Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA).

Unichem Laboratories said the product will be commercialised from its Goa plant.

Active Pharmaceutical Ingredient will also be made in-house at Roha API Plant, it added.

Shares of Unichem Laboratories were trading 1.49 per cent higher at Rs 290 on BSE.

(This article was published on April 17, 2017)

Please enter your email. Thank You.

Newsletter has been successfully subscribed.

Link:
Unichem Labs gets USFDA nod for arthritis drug - Hindu Business Line

Over 20 years, patients given drugs were apparently more able to walk, get dressed and less likely to die

RHEUMATOID arthritis sufferers given early and aggressive treatment have better and longer lives, researchers say.

Experts studied 602 patients with one in four receiving drugs within six months of showing symptoms.

Alamy

Over 20 years they were more able to walk, get dressed and less likely to die, said teams from Manchester and East Anglia Universities.

Author James Gwinnut said: Though there is a broad range in terms of how people are affected by the disease, the number of patients whose lives have improved has increased thanks in part to early treatment.

The good news is that early intervention has become more and more common in the NHS over these past 20 years.

Alamy

Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK, added: This study confirms how important early diagnosis and the commencement of treatment is.

It is also encouraging to hear about the progress that has been made over the last 20 years.

Now the scientific community must continue to build on this so that together we can continue to harness the power of exceptional science and make everyday life better for all people with arthritis.

Biomedcentral.com

The study was published in Arthritis and Rheumatology.

There are 400,000 Brits with incurable rheumatoid arthritis.

It causes inflammation in your joints with main symptoms being joint pain and swelling and flare ups.

The incurable disease leads to progressive joint destruction which leads to disability and premature death.

Excerpt from:
Rheumatoid arthritis sufferers given early and aggressive treatment live 'better and longer lives' - The Sun